Skip to main content

Table 6 Market share (patient-day based) of anticoagulants used in medically ill patients

From: Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge

Anticoagulant drug

No. of patients (%)

Days' supply per patient (mean)

Total days' supply

Days' supply per patient

No. of prescriptions

No. of prescriptions (inpatient)

No. of prescriptions (outpatient)

    

Q1

Median

Q3

   

LMWH

3390 (30.44)

6.30

21,367

2

4

7

17,358

16,865

493

Warfarin

1629 (14.63)

21.49

35,004

2

4

10

8207

7375

832

UFH

3531 (31.71)

5.24

18,508

1

3

6

18,189

15,162

3027

Fondaparinux

42 (0.38)

12.98

545

2

6

9

188

120

68

  1. LMWH, low molecular weight heparin; UFH, unfractionated heparin.